Full-Time
Test Automation Lead
Posted on 6/20/2026
Amgen
10,001+ employees
Biotech company creating biologic medicines
No salary listed
Hyderabad, Telangana, India
In Person
 QA & Testing |
|---|
- Any degree and 5 to 9 years of Computer Science, IT or related field experience
- Define and own the Test Automation Strategy for SAP ERP applications
- Identify and finalize the scope and feasibility of automation across functional, regression, and integration testing
- Work closely with Functional Test Leads, SAP Consultants, and Business stakeholders to align automation goals with project timelines
- Design, develop, and enhance automation frameworks using UFT and TOSCA
- Develop, review, and maintain automation test scripts with strong focus on reusability and scalability
- Ensure effective regular maintenance of automation assets to handle application changes
- Plan and execute automated test cycles (Regression, Smoke, Sanity)
- Analyze automation execution results and identify defects, failures, and root causes
- Prepare and publish Test Execution Reports, automation coverage metrics, and quality dashboards for project and management reviews
- Manage automation assets, execution schedules, and defects using ALM
- Support integration of automation suites with CI/CD pipelines (Jenkins or similar tools)
- Follow best practices for code versioning, reviews, and automation standards
- Mentor junior automation testers and provide technical guidance
- Strong experience in Test Automation for SAP ERP applications and other Web applications
- Hands-on expertise with ALM
- UFT
- TOSCA
- Mandatory experience in VB Scripting
- Solid understanding of Test Strategy and Automation Planning; Automation Framework Design; Test Script Development & Maintenance; Test Execution Reporting and Metrics
- Automation tools and technologies: Selenium, Playwright or similar
- Programming / Scripting: JavaScript, Type Script
- Code Management: GitHub, Bitbucket, or similar version control tools
- CI/CD & DevOps exposure: Jenkins or equivalent
- Experience in integrating automation with DevOps pipelines
- Experience in SAP modules (e.g., SD, MM, FI, CO)
- Strong analytical and problem solving skills
- Ability to work independently and lead automation initiatives end to end
- Good communication skills
Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.
Company Size
10,001+
Company Stage
IPO
Headquarters
Thousand Oaks, California
Founded
1980
Your Connections
People at Amgen who can refer or advise you
Simplify's Take
What believers are saying
- 2026 revenue guidance of $37.0 billion to $38.4 billion signals continued growth.[5]
- MariTide Phase 3 could create a differentiated obesity franchise with infrequent dosing.[3]
- US manufacturing expansion strengthens supply capacity for launches and global biologics demand.[1][5]
What critics are saying
- Prolia and XGEVA erosion continues as patent expiration pressures legacy revenue.[4]
- Tavneos faces FDA withdrawal risk, threatening roughly $500 million in annual sales.[3]
- High debt and three-wholesaler concentration expose margins and cash flow to shocks.[2][3]
What makes Amgen unique
- Amgen combines biologics leadership with small molecules, siRNA, and AI-enabled R&D.[1]
- Six growth drivers now generate nearly 70% of product sales, reducing legacy dependence.[4][6]
- Its oncology and rare-disease franchises include first-in-class assets like IMDYLLTRA and Tavneos.[1][6]
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Conference Attendance Budget
Company News
Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.
Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.
Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.
Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.
Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.